Abstract:Tuberculosis (TB) is an ancient infectious disease. Before the availability of effective drug therapy, it had high morbidity and mortality. In the past 100 years, the discovery of revolutionary anti-TB drugs such as streptomycin, isoniazid, pyrazinamide, ethambutol and rifampicin, along with drug combination treatment, has greatly improved TB control globally. As anti-TB drugs were widely used, multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of emerged due to acquired genetic mutations, and this now presents a major problem for effective treatment. Genes associated with drug resistance have been identified, including mutations in isoniazid resistance, mutations in rifampin resistance, mutations in pyrazinamide resistance, and mutations in quinolone resistance. The major mechanisms of drug resistance include loss of enzyme activity in prodrug activation, drug target alteration, overexpression of drug target, and overexpression of the efflux pump. During the disease process, may reside in different microenvironments where it is expose to acidic pH, low oxygen, reactive oxygen species and anti-TB drugs, which can facilitate the development of non-replicating persisters and promote bacterial survival. The mechanisms of persister formation may include toxin-antitoxin (TA) modules, DNA protection and repair, protein degradation such as trans-translation, efflux, and altered metabolism. In recent years, the use of new anti-TB drugs, repurposed drugs, and their drug combinations has greatly improved treatment outcomes in patients with both drug-susceptible TB and MDR/XDR-TB. The importance of developing more effective drugs targeting persisters of is emphasized. In addition, host-directed therapeutics using both conventional drugs and herbal medicines for more effective TB treatment should also be explored. In this article, we review historical aspects of the research on anti-TB drugs and discuss the current understanding and treatments of drug resistant and persistent tuberculosis to inform future therapeutic development.

Management and Marketing of Circulation of First-Line Antituberculosis Medicines: Use of Innovative Research Technologies

The past, present and future of tuberculosis treatment.

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape

The impact of digital health technologies on tuberculosis treatment: a systematic review

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

Novel technologies: A weapon against tuberculosis

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Clinical research progress of novel antituberculosis drugs on multidrug-resistant tuberculosis

Tuberculosis chemotherapy: current drug delivery approaches

Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment

An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines

Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines

Antituberculosis drugs and new drug development

Challenges in the clinical assessment of novel tuberculosis drugs

The Production and Sales of Anti-Tuberculosis Drugs in China

Faster, Higher, Stronger: the Evolution of Clinical Perspectives on Pan-Tb

Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management

Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review

The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis